首页> 外文期刊>Diagnostic cytopathology >Internal Validation Testing For New Technologies: Bringing Telecytopathology into the Mainstream
【24h】

Internal Validation Testing For New Technologies: Bringing Telecytopathology into the Mainstream

机译:新技术的内部验证测试:将细胞病理学纳入主流

获取原文
获取原文并翻译 | 示例
           

摘要

Implementing new technology in the laboratory can improve processes and patient care, but compliance with regulatory requirements can be a significant hurdle to clear. This study provides a detailed procedure to address user training, competency assessment, and internal validation of telecytopathology simultaneously, while fulfilling regulatory requirements set forth by the College of American Pathologists and CLIA 88. Six pathologists participated in this study. Methods and materials used included a blind correlation study between diagnoses rendered via telecytopathology and via direct microscopy on 10 finalized fine needle aspiration (FNA) cases. The first step of this procedure involved each pathologist to render a diagnosis for each specimen using telecytopathology. The second step was to allow each pathologist to diagnose each specimen via direct microscopic review after a wait period of at least 6 weeks. The diagnoses rendered via telecytopathology were then compared to both the established final diagnoses and the secondary direct microscopic review diagnoses to examine interpathologist and intrapathologist reproducibility with a passing rate of 90% or better. Results of the study yielded an average concordance rate of 96.67% for interpathologist reproducibility and 95% for intrapathologist reproducibility across all participating pathologists. All participants passed the assessment with a rate of 90% or better, proving evidence of competency. This study confirmed user competency and validated telecytopathology as an effective tool for examining and diagnosing cytology FNA specimens remotely. It also satisfied regulatory compliance requirements to ensure high quality of diagnostic testing and patient care. Diagn. Cytopathol. 2015;43:3-7. (c) 2014 Wiley Periodicals, Inc.
机译:在实验室中实施新技术可以改善流程和患者护理,但是要满足法规要求可能是一个很大的障碍。这项研究提供了详细的程序,可以同时解决用户培训,能力评估和远程细胞病理学的内部验证,同时满足美国病理学家学院和CLIA 88提出的监管要求。六名病理学家参加了这项研究。使用的方法和材料包括在10个最终确定的细针穿刺(FNA)病例中,通过细胞病理学诊断和通过直接显微镜检查进行的诊断之间的盲相关性研究。该过程的第一步涉及每个病理学家使用远距细胞病理学对每个标本进行诊断。第二步是让每个病理学家在等待至少6周之后,通过直接的显微镜检查来诊断每个标本。然后将通过远距细胞病理学得出的诊断结果与既定的最终诊断结果和次级直接显微镜检查诊断结果进行比较,以90%或更高的合格率检查病理学家和病理学家的可重复性。研究结果显示,在所有参与的病理学家中,病理学家间可重复性的平均一致性率为96.67%,病理学家内可重复性的平均一致性率为95%。所有参与者均以90%或更高的比率通过了评估,证明了胜任力的证据。这项研究证实了用户的能力,并验证了远程细胞病理学是一种用于远程检查和诊断细胞学FNA标本的有效工具。它还满足法规遵从性要求,以确保诊断测试和患者护理的高质量。诊断细胞病。 2015; 43:3-7。 (c)2014年威利期刊有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号